A5009564244- PARP inhibition in cancer therapy
- Inflammasome and immune disorders
- Cancer, Lipids, and Metabolism
- RNA modifications and cancer
- CRISPR and Genetic Engineering
- Cell death mechanisms and regulation
- Cancer-related molecular mechanisms research
- Immune Cell Function and Interaction
- Ferroptosis and cancer prognosis
- DNA Repair Mechanisms
- Reproductive System and Pregnancy
- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
Tongji Hospital
2023-2025
Huazhong University of Science and Technology
2023-2025
Wenzhou Medical University
2023
Homologous recombination deficiency (HRD) is prevalent in cancer, sensitizing tumor cells to poly (ADP-ribose) polymerase (PARP) inhibition. However, the impact of HRD and related therapies on microenvironment (TME) remains elusive. Our study generates single-cell gene expression T cell receptor profiles, along with validatory multimodal datasets from >100 high-grade serous ovarian cancer (HGSOC) samples, primarily a phase II clinical trial (NCT04507841). Neoadjuvant monotherapy PARP...
In addition to their established action of synthetic lethality in tumor cells, poly(ADP-ribose) polymerase inhibitors (PARPis) also orchestrate immune microenvironment (TIME) that contributes suppressing growth. However, it remains not fully understood whether and how PARPis trigger tumor-targeting responses.
Ovarian cancer (OC) is prone to peritoneum or omentum dissemination, thus giving rise the formidable challenge of unresectable surgery and a dismal survival rate. Although niraparib holds pivotal role in maintenance treatment OC, its effect on suppressing metastases during primary intervention remains enigmatic. Recently, we initiated prospective clinical study (NCT04507841) order evaluate therapeutic efficacy neoadjuvant monotherapy for advanced OC with homologous recombination deficiency....
Abstract Endometrial cancer (EC) is one of the most common gynaecological malignant tumours with a high incidence, leading to urgent demands for exploring novel carcinogenic mechanisms and developing rational therapeutic strategies. The rac family small GTPase 3 (RAC3) functions as an oncogene in various human plays important role tumour development. However, critical roles RAC3 progression EC need further investigation. Based on TCGA, single‐cell RNA‐Seq, CCLE clinical specimens, we...
Breast and ovarian cancers are common malignancies among women, contributing to a significant disease burden, characterized by high level of genomic instability, owing the failure homologous recombination repair (HRR). Pharmacological inhibition poly(ADP-ribose) polymerase (PARP) could elicit synthetic lethal effect tumor cells in patients with deficiency, ultimately achieving favorable clinical benefit. However, primary acquired resistance remain greatest hurdle, limiting efficacy PARP...